Tuesday, July 25, 2017
Company News: Page (1) of 1 - 02/27/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Valeant Announces Deployment Of Expanded Salix Sales Force To Capture Untapped Market Opportunity
(February 27, 2017)

Significant investment in Primary Care Representatives for Key Products, Xifaxan® (rifaximin) and RELISTOR® (methylnaltrexone bromide)

LAVAL, Quebec, Feb. 27, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Salix, a leading specialty pharmaceutical company committed to the prevention and treatment of gastrointestinal (GI) disorders, today announced that it has rapidly scaled up its sales force by nearly 40 percent, effective immediately. 

"This is a demonstration of our commitment to GI and its relative importance to the broader value of our company," said Joseph C. Papa, Chairman and CEO of Valeant.  "The significant investments in Salix's dedicated Primary Care Physician (PCP) sales force will help us further reach patients in need of irritable bowel syndrome with diarrhea (IBS-D) treatment, and in doing so, will further accelerate growth for our company."

During the past three months, the company has hired approximately 250 highly-trained and experienced sales force representatives and managers to bolster, create and sustain deep relationships with primary care physicians key potential prescribers of Xifaxan® (rifaximin) for IBS-D and RELISTOR® (methylnaltrexone bromide) tablets for opioid induced constipation (OIC).  With approximately 70 percent of IBS-D patients initially presenting with symptoms to a primary care physician, the dedicated PCP sales force will be positioned to reach even more patients in need of IBS-D treatment.   

"This will complement our existing primary care team and will allow us to capture nearly 75 percent of the primary care market opportunity," said Mark McKenna, Senior Vice President and General Manager, Salix Pharmaceuticals.

In addition, the company has expanded its dedicated pain sales representatives to strengthen its position in the OIC market, and established a nurse educator team to educate clinical staff within top institutions. 

About Valeant                                                                                                    

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

About Salix

Salix Pharmaceuticals is one of the largest gastrointestinal specialty pharmaceuticals companies in the world.  Salix develops and markets prescription pharmaceuticals products and medical devices for the prevention and treatment of gastrointestinal diseases and disorders. For more information on Salix Pharmaceuticals, visit www.salix.com.

Forward-looking Statements

This press release contains forward-looking statements.  Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Readers are cautioned not to place undue reliance on any of these forward-looking statements.  These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes, unless required by law.

Contact Information:

Elif McDonald
877-281-6642 (toll free)

Renée Soto
Chris Kittredge/Jared Levy
Sard Verbinnen & Co.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/valeant-announces-deployment-of-expanded-salix-sales-force-to-capture-untapped-market-opportunity-300413767.html

SOURCE Valeant Pharmaceuticals International, Inc.

Copyright 2014 PR Newswire. All Rights Reserved

Page: 1

Related Keywords: Inc., Technology, Surgery, Physician, Nurse, Science, Medical Technology, Medical, Medical Professionals,
Related Sites: HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter

  • Global Neuropsychiatric Disorders And Treatment Market Is Expected To Grow At A CAGR Of 6.2% During Forecast 2023
  • ChiRhoStim® (Human Secretin for Injection) FDA approved labeling update and 5-year shelf life approval
  • Wound Closure and Advanced Wound Care Global Market Forecast To 2023
  • Longeveron to Sponsor Industry Symposium on Regenerative Medicine at 2017 IAGG World Congress
  • Regenerative Medicine Market Size Worth $5.59 Billion by 2025: Grand View Research, Inc.

  • After 20 Years of Scrutiny Researchers Confirm Surgery for Early Prostate Cancer May Not Save Lives
  • Varian to Showcase Latest Radiotherapy and Radiosurgery Technologies and Software at AAPM 2017
  • American Brain Tumor Association's Annual Patient and Family Conference to Address Physical and Cognitive Symptoms and Side Effects
  • St. Jude Children's Research Hospital®, ALSAC Announce Chairs of Boards of Directors and Governors
  • Montgomery Gentry Headlines 9th Annual Country on the Beach in Key West, Florida Benefitting the T.J. Martell Foundation

    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines